How a 64-Year-Old Patient from Malaysia Accessed a Leading US Oncologist for a Stage IV Colon Cancer Remote Second Opinion
- Medebound HEALTH
- Jun 4
- 10 min read
Introduction
When Aurelia (alias) received the results of her CT scan on a November morning in Seremban, Malaysia, she had hoped for clarity. Instead, she was handed a treatment plan involving arterial chemotherapy injections targeting her liver — and a quiet, persistent feeling that something wasn't right.
Aurelia is a 64-year-old woman — a non-smoker, health-conscious, and, until recently, someone with no significant medical history beyond a fibroid removal decades earlier and a bilateral mastectomy in her early fifties as a precaution against suspected early breast changes. She had never had a colonoscopy before the autumn of 2025.
The diagnosis she received that November was stage IV transverse colon cancer — in plain terms, an advanced cancer of the large intestine that had already spread to her liver, her peritoneum (the lining of the abdominal cavity), and nearby lymph nodes. It was serious, and the proposed treatment path was aggressive.
But Aurelia — and her family, who had been researching her case intensively — was not sure it was the right path. This is the story of how she came to seek a specialist second opinion from one of the United States' leading gastrointestinal oncologists, what that review revealed, and what it meant for her treatment.
The Diagnosis and the First Treatment Plan
In mid-November 2025, Aurelia presented to Mawar Medical Centre in Seremban with symptoms of intestinal obstruction — in plain terms, a blockage in her bowel. A contrast-enhanced CT (CECT) scan — an imaging technique that uses dye to highlight internal structures — revealed a substantial mass in the mid-transverse colon measuring 5.5 centimetres in length, along with suspected spread to the liver and pelvic cavity.
On 21 November 2025, she underwent major surgery: a mid-transverse colon resection combined with a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO) — in plain terms, surgeons removed the affected section of bowel, the uterus, and both ovaries and fallopian tubes, as the tumor had spread directly into those organs. A small intestine stoma — an opening in the abdominal wall to allow waste to pass into an external bag — was created as part of the procedure.
Pathology results from the surgery confirmed the most serious findings. The tumor had grown completely through the bowel wall and the surgical margins. Of 19 lymph nodes and tumor nodules examined in the surrounding tissue, all 19 showed cancer involvement. Metastatic deposits were confirmed in the uterus and cervix. A follow-up PET-CT scan in December further identified active cancer in segment 4b of the liver, in the peritoneum (abdominal lining), and in a celiac axis lymph node (a group of nodes near major abdominal blood vessels). Her formal staging was pT4N2M1 — meaning the primary tumour had grown through the full bowel wall and invaded surrounding structures (T4), with extensive lymph node involvement (N2), and confirmed distant metastases (M1).
On 29 December 2025, she began arterial perfusion chemotherapy — a localised treatment where drugs are delivered directly through the blood vessels supplying the liver and other abdominal vessels. The medications used were oxaliplatin (a platinum-based chemotherapy) and fluorouracil (a chemotherapy drug that interferes with cancer cell growth).
"We were told this was the best approach for reaching the liver. But as we read more, we kept asking: what about the other sites? What about the lymph nodes and the peritoneum? We weren't sure this treatment could reach all of them." — Aurelia's family
The concern was not with the quality of care they had received. It was a genuine clinical question: was a localised, artery-based treatment the right strategy for a cancer that had clearly spread to multiple sites across the body?
Why She Decided to Seek a Second Opinion
For Aurelia's family, the decision to seek a second opinion was not made lightly. There was deep respect for the treating team in Malaysia and China, and no desire to imply criticism. But several specific concerns had accumulated:
The cancer had spread to the peritoneum and celiac lymph nodes — areas that, by their nature, are difficult to reach with a treatment targeting only specific arteries
Aurelia had lost significant weight and weighed only 43 kg — any treatment decision had to account for her physical tolerance
Her genetic profile had revealed a KRAS mutation (p.G12V) — a clinically significant finding with potential implications for treatment selection and future clinical trials
The family had seen research suggesting that standard systemic chemotherapy — delivered through a vein to reach the whole body — was the evidence-based approach for metastatic colon cancer of this type
They discovered Medebound HEALTH through an online search and reached out to inquire about accessing a specialist in gastrointestinal oncology in the United States.
"We needed someone outside of our immediate situation to look at everything — the full picture — and tell us honestly what they saw." — Aurelia's family
The Second Opinion Process: Step by Step
Through Medebound HEALTH, Aurelia's family submitted a comprehensive set of clinical records for specialist review. These included:
CT and PET-CT scan reports and imaging files
Surgical and pathology reports from the November 2025 resection
Full genomic sequencing results (whole-exome sequencing across more than 20,000 genes)
Blood work, tumor markers, and haematology reports dating from November 2025 through January 2026
Current medication list and recent laboratory findings including MRD (minimal residual disease) test results
The reviewing specialist — referred to here as Dr. Moretz, a Professor of Gastrointestinal Medical Oncology with current appointment at MD Anderson, a researcher with particular expertise in colorectal cancer and immunotherapy, and a physician recognised among the top 1% of oncologists nationally — conducted a thorough review of all submitted records. A video consultation was held with the family on 19 January 2026, followed by a formal written opinion delivered on 20 January 2026.
Dr. Moretz's written opinion ran to a detailed, structured clinical assessment — covering treatment comparison, specific dosing recommendations, genetic findings, alternative plans if initial treatment failed, supportive care, and prognosis.
What the Specialist Found: A Fundamentally Different Treatment Approach
The core of Dr. Moretz's assessment centred on a fundamental question that had been troubling Aurelia's family all along: was localised arterial chemotherapy — targeting specific blood vessels — the right approach for a cancer that had spread to the peritoneum and abdominal lymph nodes?
His answer was direct. The peritoneal disease and the retroperitoneal lymph node involvement (at the celiac axis) were the critical factors. These are sites — in plain terms, locations in the body — where localised arterial treatments simply cannot reach effectively. Treating only the liver with a targeted arterial approach, when cancer was also present in the abdominal lining and distant lymph nodes, would leave the bulk of the disease untouched.
Treatment Comparison: Local vs. Systemic Approach
Factor | Arterial Perfusion Chemotherapy (Current) | Systemic IV Chemotherapy (FOLFOX + Bevacizumab) |
Coverage | Local — liver and targeted arterial zones only | Systemic — reaches all disease sites including peritoneum and lymph nodes |
Evidence Base | Limited data for this indication; no established benefit for peritoneal disease | Extensive clinical data; used in millions of patients with proven efficacy |
Suitability for Aurelia's Disease Pattern | Not appropriate — cannot treat peritoneal or lymph node metastases | Appropriate — designed for multi-site metastatic disease |
Dose Intensity (Aurelia's Current Schedule) | 21-day cycles — approximately two-thirds of the standard dose intensity | 14-day cycles — standard dose intensity; can start at lower dose and escalate based on tolerance |
Dr. Moretz's specific treatment recommendation was FOLFOX + bevacizumab — a standard systemic intravenous chemotherapy regimen. In plain terms, this means drugs delivered through a vein into the bloodstream, where they can travel to every site where cancer is present.
The regimen involves three drugs: oxaliplatin (a platinum-based agent), 5-fluorouracil or 5-FU (a drug that disrupts cancer cell replication), and bevacizumab (also known by the brand name Avastin — a targeted therapy that cuts off the blood supply feeding tumor growth). Cycles run every 14 days, and the specialist noted that starting oxaliplatin at a slightly lower dose and escalating based on how well Aurelia tolerated it was a reasonable approach.
Regarding the existing 21-day treatment cycle Aurelia was on, Dr. Moretz noted that the dose intensity was equivalent to only approximately two-thirds of the standard weekly dose — a clinically meaningful difference that he considered suboptimal.
He also addressed Aurelia's genetic findings. Her tumor carried a KRAS p.G12V mutation — in plain terms, a specific alteration in a gene that regulates cell growth. This finding has two important implications: it means that certain antibody-based targeted therapies (cetuximab and panitumumab) would not work for her, and it opens a potential future pathway to KRAS inhibitor clinical trials, which are currently in development. However, Dr. Moretz was clear that KRAS-targeting drugs are not yet approved for standard use, and that Aurelia first needed to complete standard chemotherapy lines to become eligible for trial entry. The first-line FOLFOX + bevacizumab regimen, he noted, offers an approximately 60% tumor shrinkage response rate — significantly stronger than KRAS inhibitors' current 20–30% rate.
On monitoring, Dr. Moretz recommended PET/CT or regular CT scans every two months to assess treatment response. Key indicators of success would be stabilisation or shrinkage of tumor lesions; key warning signs would be appearance of new lesions, persistent weight loss, or inability to tolerate the regimen.
Aurelia's Decision: Clarity After Months of Uncertainty
For Aurelia and her family, receiving the second opinion report was not a moment of relief so much as a moment of clarity. The question that had sat uncomfortably since December — could the current treatment actually reach all the cancer? — now had a considered, expert answer.
The family spent time reviewing the written report carefully. They took the specialist's recommendations back to Aurelia's treating oncologist in China and Malaysia. The second opinion was not framed as a challenge to anyone's competence; it was framed as additional expert input to inform a difficult decision.
"This was the most important medical decision of my life. I needed to know that we had looked at everything, asked the right people, and made the best choice we could with the best information available." — Aurelia
The process did what a well-conducted second opinion is meant to do: it gave the patient and her family the information to make a genuinely informed decision, with their eyes open to both the clinical rationale and the realistic prognosis.
Treatment and Outlook
At the time the second opinion was delivered in January 2026, Aurelia had completed one cycle of arterial perfusion chemotherapy and was approaching her second cycle. The second opinion report was received before that cycle began, making the timing significant: Dr. Moretz specifically recommended adding bevacizumab at the next chemotherapy round rather than waiting.
Her laboratory picture at the time of the review showed several notable findings: her tumor marker CA 19-9, a blood test used to track colorectal cancer activity, had risen to 307.8 U/ml (normal range below 32) — a signal of active disease. Her weight had declined to 43 kg — a concern, given that maintaining weight is considered a critical factor in being able to continue chemotherapy treatment. Dr. Moretz's supportive care recommendations specifically addressed weight maintenance as the primary priority: high-calorie nutritional supplementation, adequate fluid intake, and appropriate gentle exercise, alongside cautious use of supportive therapies.
On prognosis, Dr. Moretz was clear and compassionate. For KRAS-mutated transverse colon cancer classified as right-sided — which carries a distinct biological behaviour — the average survival with standard chemotherapy is approximately two years. The goal of treatment at this stage is not cure, but control of disease progression, prolongation of survival, and maintenance of quality of life. Understanding this honestly was, Aurelia and her family said, itself important — it helped them focus on what mattered most.
Individual results will vary. The outlook described reflects this patient's specific clinical circumstances. Speak with your own physician to understand what may be realistic for your situation.
What Aurelia's Story Teaches Us About Second Opinions
Aurelia's case illustrates several lessons that are worth understanding for any patient navigating a complex or serious diagnosis:
The treatment question matters as much as the diagnosis. A cancer diagnosis is confirmed through pathology. But the treatment plan is a clinical judgment — and different specialists, drawing on different experiences and evidence bases, can reach different conclusions. In Aurelia's case, the fundamental treatment question (local versus systemic therapy) carried major implications for whether her disease could be controlled.
Genetic findings require specialist interpretation. Aurelia's genomic sequencing report flagged a KRAS mutation and several other findings. The second opinion provided a clear, prioritised interpretation: which mutations were actionable, what they meant for current treatment, and what future pathways they might open.
A second opinion is an act of self-advocacy, not disloyalty. Multiple studies — including research published by the Mayo Clinic — have found that second opinions lead to changes in diagnosis or management plans in approximately one in three cases. Seeking expert review is not a criticism of a treating physician; it is a patient exercising their right to informed decision-making.
Geography is no longer a barrier. Aurelia accessed a Professor of Gastrointestinal Medical Oncology affiliated with MD Anderson, a leading US cancer institution without leaving Malaysia. Cross-border medical review services now make it possible for patients anywhere in the world to access highly specialised expertise through structured, secure processes.
Honest prognosis enables better living. Understanding the realistic outlook — while difficult — allowed Aurelia and her family to make choices about how to use the time ahead, what mattered most, and where to focus their energy.
How Medebound HEALTH Connects International Patients to Top U.S. Cancer Experts
Medebound HEALTH is a U.S.-based medical coordination service that facilitates second opinions from independent U.S.-licensed physicians affiliated with leading cancer centers such as MD Anderson, Mayo Clinic, Memorial Sloan Kettering and Johns Hopkins. Since 2016, the service has supported 3000+ international patients, primarily from Asia, seeking expert input before major oncology decisions.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Your Next Step
If you or someone you care for has received a cancer diagnosis — or any serious medical diagnosis — and you are uncertain about the recommended treatment plan, a second opinion from an internationally recognised specialist can give you the clarity to move forward with confidence.
Medebound HEALTH connects patients across Asia and beyond with top-tier physicians at leading US cancer and medical institutions, including specialists recognised by Castle Connolly as among the top 1% of physicians in their fields. The process is straightforward: submit your medical records, and a specialist will review your case and provide a detailed written opinion — typically within days.
A Patient Navigator can walk you through every step of the process, explain what records are needed, and help you understand the report you receive.
Is a Second Opinion Right for Your Situation?
If you or someone in your family has received a diagnosis that feels uncertain, a treatment plan that raises questions, or a disease that has returned or changed—you do not have to navigate that alone.
A 20-minute, no-obligation case review with a Medebound HEALTH Advisor will help you understand whether a specialist review is appropriate for your situation, which type of specialist would be most relevant, and what the process involves, step by step. There is no pressure and no commitment. The conversation begins with your questions.
Disclaimer
We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician. The service is independently operated by Medebound HEALTH and is not provided, partnered, or affiliated with any hospital center as an institution.
